Literature DB >> 30156088

Assistive powered exoskeleton for complete spinal cord injury: correlations between walking ability and exoskeleton control.

Eleonora Guanziroli1,2, Maurizio Cazzaniga3, Laura Colombo3, Sabrina Basilico3, Giovanni Legnani4, Franco Molteni3.   

Abstract

BACKGROUND: Wearable powered robotic exoskeletons allow patients with complete spinal cord injury (SCI) to practice over-ground real-world gait scenarios. The global functional interaction subject-exoskeleton is a key factor to produce interlimb coordinated movements. Efficacy and efficiency of over-ground walking abilities using powered exoskeletons are related not only to the symbiotic sensory-motor interaction subject-exoskeleton but also to exoskeleton control. AIM: Assess if walking ability of motor complete SCI patients at thoracic or lower level, using a wearable powered exoskeleton (ReWalk), can be influenced by different exoskeleton software control.
DESIGN: Observational study; an open, non-comparative, non-randomized study.
SETTING: A single neurological rehabilitation center for inpatients and outpatients. POPULATION: Fifteen SCI chronic patients (4 females and 11 males) were recruited and divided in two groups: group 1, trained with the first software generation of ReWalk, and group 2, trained with the second software generation, a software upgrade of the previous version.
METHODS: Subjects were trained during three 60-minute sessions a week, during at least eight weeks using ReWalk, a wearable lower limb powered exoskeleton that allows thoracic or lower level motor-complete individuals with SCI to walk, stand, sit and climb/descend stairs. Outcome measures, collected at the end of the training period wearing the exoskeleton, were: 6-min Walking Test, 10-m Walking Test, and the time necessary to pass from sitting to standing and start to walk (STS-time). For each group Pearson Coefficient was calculated to explore correlations between the subjects' characteristics and gait performance reached at the end of the training period.
RESULTS: Group 1 showed correlation between performances and weight, height, neurological lesion level, while group 2 showed no correlation between performances weight and height, but correlation only with neurological lesion level. Group 2 covered more distance in 6 min (+124.52%) and required less time (-70.34%) to perform 10 mtWT and to STS-time (-38.25%) if compared to group 1.
CONCLUSIONS: ReWalk allows chronic complete spinal cord injury patients to perform over-ground walking. Different exoskeleton software control of the smoothness of the gait pattern improves functional outcome, eliminating the relationship between anthropometric factors and gait performances. The smoothness of the kinematic control of the lower limbs of the exoskeleton is a key factor to facilitate human-robot interaction and to increase walking abilities of the subject. CLINICAL REHABILITATION IMPACT: To underline how the kinematic control of the exoskeleton influences the walking abilities of the complex system subject-exoskeleton.

Entities:  

Year:  2018        PMID: 30156088     DOI: 10.23736/S1973-9087.18.05308-X

Source DB:  PubMed          Journal:  Eur J Phys Rehabil Med        ISSN: 1973-9087            Impact factor:   2.874


  9 in total

1.  The safety and feasibility of a new rehabilitation robotic exoskeleton for assisting individuals with lower extremity motor complete lesions following spinal cord injury (SCI): an observational study.

Authors:  Xiao-Na Xiang; Ming-Fu Ding; Hui-Yan Zong; Yan Liu; Hong Cheng; Cheng-Qi He; Hong-Chen He
Journal:  Spinal Cord       Date:  2020-02-07       Impact factor: 2.772

Review 2.  Sensors and Actuation Technologies in Exoskeletons: A Review.

Authors:  Monica Tiboni; Alberto Borboni; Fabien Vérité; Chiara Bregoli; Cinzia Amici
Journal:  Sensors (Basel)       Date:  2022-01-24       Impact factor: 3.576

3.  TWIICE One powered exoskeleton: effect of design improvements on usability in daily life as measured by the performance in the CYBATHLON race.

Authors:  Tristan Vouga; Jemina Fasola; Romain Baud; Ali Reza Manzoori; Julien Pache; Mohamed Bouri
Journal:  J Neuroeng Rehabil       Date:  2022-06-27       Impact factor: 5.208

4.  Exoskeleton-assisted walking improves pulmonary function and walking parameters among individuals with spinal cord injury: a randomized controlled pilot study.

Authors:  Xiao-Na Xiang; Hui-Yan Zong; Yi Ou; Xi Yu; Hong Cheng; Chun-Ping Du; Hong-Chen He
Journal:  J Neuroeng Rehabil       Date:  2021-05-24       Impact factor: 4.262

5.  Dynamic Margins of Stability During Robot-Assisted Walking in Able-Bodied Individuals: A Preliminary Study.

Authors:  Arvind Ramanujam; Kamyar Momeni; Manikandan Ravi; Jonathan Augustine; Erica Garbarini; Peter Barrance; Ann M Spungen; Pierre Asselin; Steven Knezevic; Gail F Forrest
Journal:  Front Robot AI       Date:  2020-12-09

Review 6.  Wearable robotic exoskeleton for gait reconstruction in patients with spinal cord injury: A literature review.

Authors:  Koki Tan; Soichiro Koyama; Hiroaki Sakurai; Toshio Teranishi; Yoshikiyo Kanada; Shigeo Tanabe
Journal:  J Orthop Translat       Date:  2021-03-01       Impact factor: 5.191

7.  Wearable Power-Assist Locomotor for Gait Reconstruction in Patients With Spinal Cord Injury: A Retrospective Study.

Authors:  Soichiro Koyama; Shigeo Tanabe; Takeshi Gotoh; Yuta Taguchi; Masaki Katoh; Eiichi Saitoh; Yohei Otaka; Satoshi Hirano
Journal:  Front Neurorobot       Date:  2022-02-18       Impact factor: 2.650

Review 8.  Current Concepts of Neural Stem/Progenitor Cell Therapy for Chronic Spinal Cord Injury.

Authors:  Hidenori Suzuki; Yasuaki Imajo; Masahiro Funaba; Norihiro Nishida; Takuya Sakamoto; Takashi Sakai
Journal:  Front Cell Neurosci       Date:  2022-02-03       Impact factor: 5.505

Review 9.  Overground robotic training effects on walking and secondary health conditions in individuals with spinal cord injury: systematic review.

Authors:  Federica Tamburella; Matteo Lorusso; Marco Tramontano; Silvia Fadlun; Marcella Masciullo; Giorgio Scivoletto
Journal:  J Neuroeng Rehabil       Date:  2022-03-15       Impact factor: 4.262

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.